Adia Nutrition Launches Second National Television Campaign Showcasing U.S.-Based Regenerative Stem Cell Therapies
Adia Nutrition (OTCQB: ADIA) has launched its second national television campaign highlighting Adia Med's regenerative stem cell treatments at its Winter Park, Florida clinic. The campaign emphasizes U.S.-based therapies for conditions including sports injuries, orthopedic care, chronic pain, and wound repair.
The company is targeting the $25 billion wound care market and aims to make regenerative therapies more accessible domestically. Adia Med is currently in-network with UnitedHealthcare and Aetna, with pending TRICARE approval. The initiative is supported by favorable legislation like Florida's SB1768, which recognizes stem cell therapy benefits.
Adia Nutrition (OTCQB: ADIA) ha lanciato la sua seconda campagna televisiva nazionale, promuovendo i trattamenti rigenerativi con cellule staminali di Adia Med presso la clinica di Winter Park, Florida. La campagna mette in risalto terapie statunitensi per lesioni sportive, cure ortopediche, dolore cronico e riparazione delle ferite.
L'azienda punta al mercato della cura delle ferite da 25 miliardi di dollari e vuole rendere le terapie rigenerative più accessibili a livello nazionale. Adia Med è attualmente in rete con UnitedHealthcare e Aetna, con l'approvazione TRICARE in attesa. L'iniziativa è favorita anche da normative come la SB1768 della Florida, che riconosce i benefici della terapia con cellule staminali.
Adia Nutrition (OTCQB: ADIA) ha lanzado su segunda campaña nacional en televisión, destacando los tratamientos regenerativos con células madre de Adia Med en su clínica de Winter Park, Florida. La campaña pone énfasis en terapias basadas en EE. UU. para lesiones deportivas, atención ortopédica, dolor crónico y reparación de heridas.
La compañía se dirige al mercado de cuidado de heridas de 25.000 millones de dólares y busca que las terapias regenerativas sean más accesibles dentro del país. Adia Med está actualmente dentro de la red de UnitedHealthcare y Aetna, con la aprobación de TRICARE pendiente. La iniciativa cuenta con el respaldo de leyes favorables como la SB1768 de Florida, que reconoce los beneficios de la terapia con células madre.
Adia Nutrition (OTCQB: ADIA)는 플로리다 윈터파크 클리닉에서 Adia Med의 재생 줄기세포 치료를 소개하는 두 번째 전국 TV 캠페인을 시작했습니다. 이 캠페인은 스포츠 부상, 정형외과 치료, 만성 통증 및 상처 치유를 위한 미국 내 치료법을 강조합니다.
회사는 250억 달러 규모의 상처 치료 시장을 겨냥하고 있으며 재생 치료를 국내에서 더 쉽게 이용할 수 있도록 하는 것을 목표로 합니다. Adia Med는 현재 UnitedHealthcare와 Aetna의 네트워크에 포함되어 있으며 TRICARE 승인은 심사 중입니다. 이 계획은 줄기세포 치료의 이점을 인정하는 플로리다 법안 SB1768과 같은 우호적인 입법의 지원을 받고 있습니다.
Adia Nutrition (OTCQB: ADIA) a lancé sa deuxième campagne télévisée nationale mettant en avant les traitements régénératifs par cellules souches d'Adia Med dans sa clinique de Winter Park, en Floride. La campagne met l'accent sur des thérapies basées aux États-Unis pour les blessures sportives, les soins orthopédiques, la douleur chronique et la réparation des plaies.
L'entreprise vise le marché des soins des plaies de 25 milliards de dollars et cherche à rendre les thérapies régénératives plus accessibles au niveau national. Adia Med fait actuellement partie des réseaux de UnitedHealthcare et Aetna, l'approbation TRICARE étant en attente. L'initiative bénéficie également d'un cadre législatif favorable, comme la SB1768 de Floride, qui reconnaît les bienfaits de la thérapie par cellules souches.
Adia Nutrition (OTCQB: ADIA) hat seine zweite nationale Fernsehkampagne gestartet, in der Adia Meds regenerative Stammzellbehandlungen in der Klinik in Winter Park, Florida, vorgestellt werden. Die Kampagne hebt in den USA angesiedelte Therapien für Sportverletzungen, orthopädische Versorgung, chronische Schmerzen und Wundheilung hervor.
Das Unternehmen richtet sich an den 25-Milliarden-Dollar-Wundversorgungsmarkt und will regenerative Therapien national besser zugänglich machen. Adia Med ist derzeit im Netzwerk von UnitedHealthcare und Aetna, die TRICARE-Zulassung steht noch aus. Die Initiative wird durch günstige Gesetzgebung wie Floridas SB1768 unterstützt, die die Vorteile der Stammzelltherapie anerkennt.
- Entry into the large $25 billion wound care market
- In-network status with major insurers UnitedHealthcare and Aetna
- Favorable regulatory environment with Florida's SB1768 legislation
- Strategic expansion through licensing opportunities and partnerships
- Operating in a highly competitive regenerative medicine market
- Pending TRICARE approval indicates incomplete insurance coverage
Winter Park, Florida--(Newsfile Corp. - August 21, 2025) - Adia Nutrition Inc. (OTCQB: ADIA), a publicly traded leader in regenerative medicine and personalized healthcare, today announced the launch of its second nationwide television campaign. The commercial highlights Adia Med, the company's clinical division, and its advanced regenerative stem cell treatments now available at the flagship Winter Park, Florida clinic. These therapies are designed for a wide range of conditions including sports injuries, orthopedic care, chronic pain, and advanced wound repair.
Adia Nutrition launches second nationwide commercial
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/10520/263215_adia.jpg
The TV campaign comes on the heels of Adia Med's entry into the
Click Here to Watch Commercial
"This nationwide commercial is about showing patients they don't need to leave the country to get access to cutting-edge regenerative medicine," said Larry Powalisz, CEO of Adia Nutrition Inc. "It's available right here at home, and we're doing it in a way that meets the highest U.S. medical standards. For patients, it means better access and peace of mind. For investors, it represents a growing market opportunity that we are well-positioned to lead."
Momentum is also being supported by favorable policy trends, including Florida's passage of SB1768, which formally recognizes the regenerative benefits of stem cell therapy. This legislation underscores the growing legitimacy of regenerative medicine in the U.S. and strengthens Adia Med's position as a pioneer in the field.
The new commercial, airing on major TV networks, presents Adia Med as a destination clinic for regenerative healthcare. Treatments focus on accelerating recovery, improving mobility, and enhancing quality of life, while avoiding the need for costly and burdensome medical travel abroad.
Adia Med is currently an in-network provider with UnitedHealthcare and Aetna, with an active filing underway with TRICARE to broaden access further. The campaign is both a brand-building milestone and a patient acquisition engine, reinforcing Adia's mission to deliver regenerative therapies that are accessible, affordable, and nationally recognized.
For questions, inquiries, or additional information, please contact Larry Powalisz at ceo@adiamed.com or by phone at 321-788-0850.
Clinic owners and healthcare practitioners interested in licensing the Adia Med name or integrating Adia's regenerative therapies into their practice are encouraged to reach out directly. Strategic partnerships are welcomed as part of Adia's continued mission to expand access to advanced stem cell solutions.
About ADIA Nutrition Inc.:
Adia Nutrition Inc. is a publicly traded company (OTCQB: ADIA) dedicated to revolutionizing healthcare and supplementation. With a focus on innovation and quality, the company has established two key divisions: a supplement division providing premium, organic supplements, and a medical division establishing Clinics that specialize in leading-edge stem cell therapies, most significantly Umbilical Cord Stem Cells (UCB-SC) and Autologous Hematopoietic Stem Cell Transplantation (aHSCT) treatments. Through these divisions, Adia Nutrition Inc. is committed to empowering individuals to live their best lives by addressing both nutritional needs and groundbreaking medical treatments.
Website: www.adianutrition.com
Website: www.adiamed.com
Website: www.adialabs.com
Website: www.biolete.com
Website: www.cementfactory.co
Twitter (X): @ADIA_Nutrition
Safe Harbor: This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a few uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, because of new information, future events or otherwise.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/263215
FAQ
What treatments does Adia Med (OTCQB: ADIA) offer in its stem cell therapy program?
Which insurance providers cover Adia Med's stem cell treatments?
What is the size of the wound care market that Adia Nutrition is targeting?
How does Florida's SB1768 legislation affect Adia Med's business?
Where is Adia Med's flagship stem cell treatment clinic located?
